Neonc Technologies Holdings, Inc. · NASDAQ:NTHI
Neonc Technologies — Investor Presentation (March 2026)
59 slides from Neonc Technologies's investor presentation, March 2026
Slide 1: Removing Barriers to Effective Neuro-Drug Delivery
NTHI Removing Barriers to Effective Neuro-Drug Delivery Corporate Presen ta tio n 2026
Slide 2: Important Cautions Regarding Forward Looking Statements
Important Cautions Regarding Forward Looking Statements This document does not constitute or form part of an invitation or We have based the forward-looking statements on our current expectations and recommendation to subscribe for or purchase any securities. The distribution projections about futur
Slide 3: Senior Management Team, Board of Directors, Scientific Advisory Board
Senior Management Team Board of Directors Scientific Advisory Board
Slide 4: The Problem: Recurrent Brain Tumors Are Untreatable
The Problem: Recurrent Brain Tumors Are Untreatable Relapse is inevitable 90% of high-grade glioma patients recur within 6–9 months despite maximal therapy Clinical focus at recurrence is overall survival, not partial response In recurrent disease, relapse is expected; objective responses rarely tra
Slide 5: A Next-Generation Neuro-Oncology Company Built on Two Proprietary Platforms
A Next-Generation Neuro-Oncology Company Built on Two Proprietary Platforms Drug Delivery Platform (NEO100) Drug Conjugation Platform (NEO212) Carbamide Bond NEO100 Temozolomide (TMZ) • Direct, non-invasive CNS delivery powered by patented technology • Patented platform enables targeted, non-invasiv
Slide 6: Phase 2 Development & Clinical Pipeline
Phase 2 Development & Clinical Pipeline Important Disclaimer: This development & clinical pipeline is subject to regulatory approval, risk and uncertainties, as well as potential changes to the pipeline and other factors that are beyond our control. FDA Authorized Clinical Trials Drug IND Applicatio
Slide 7: NEO100
NEONC NEO100
Slide 8: NEO100: Foundation of a Next-Generation Drug Delivery and Tumor-Treating Platform
NEO100: Foundation of a Next- Generation Drug Delivery and Tumor-Treating Platform Proprietary Chemistry: NEO100 is a patented, ultra-pure pharmaceutical compound derived from Perillyl Alcohol (POH), a natural substance found in citrus and peppermint oils. Innovative Synthesis: Using a proprietary c
Slide 9: NEO100 (POH) Efficacy in Temozolomide-Resistant Gliomas
NEO100 (POH) Efficacy in Temozolomide-Resistant Gliomas Mechanism-Driven Second-Line Opportunity: NEO100 induces ER stress in TMZ-resistant brain tumors while inhibiting Na⁺/K⁺-ATPase and downregulating RAS—supporting its clinical development as a second-line therapy for HGG patients progressing on
Slide 10: With three mechanisms of action, NEO100 is designed to corner and combat tumors
With three mechanisms of action, NEO100 is designed to corner and combat tumors from all sides. NEO100 1 3 2 Cytoplasmic RAS Oncoprotein Na/K-ATPase Membrane Inhibition Inhibition Disruption Electrolyte Imbalance (Na+, K+, Ca++) Endoplasmic Reticulum Stress (Unfolded Protein Response) Garcia DG et a
Slide 11: IDH1-Mutant Grade 3 & 4 Astrocytomas: Critical Unmet Need
IDH1-Mutant Grade 3 & 4 Astrocytomas: Critical Unmet Need Meaningful patient population with advanced disease Approximately 15,000–18,000 patients with IDH1-mutant glioma across the U.S. and EU; an estimated ~35–45% present with or progress to Grade 3 or Grade 4 disease over time Current treatment p
Slide 12: NEO100 Phase I Clinical Trial Results
NEO100 Phase I Clinical Trial Results Unmet Need: Recurrent GBM after radiation + temozolomide; historical median OS ~6–9 months Trial Design: multi-center U.S. study (n=12), continuous intranasal dosing until progression Dosing: 384–1,152 mg/day, 4× daily; non-invasive CNS-targeted delivery Safety:
Slide 13: NEO100 Phase I Survival Data
NEO100 Phase I Survival Data NEO100 OVERALL SURVIVAL RATES NEO100 TREATMENT CYCLE NEO100 TREATMENT OF SURVIVAL RATES PATIENTS WITH IDH1 MARKER Survival Survival Survival % OS12 MEDIAN OS24 % % 55% OS 33% COMPLETED HAS IDH1 MORE THAN MUTATIONS 5 TREATMENT CYCLES COMPLETED LESS THAN 5 TREATMENT NO IDH
Slide 14: Before & After NEO100 Treatment
Before & After NEO100 Treatment January 2023 October 2023 Brain Scan Shows Significant Tumor Reduction at Nine Months Following Treatment with NEO100 14
Slide 15: NEO100 vs. 2nd-Line Recurrent Brain Tumor Benchmarks
NEO100 vs. 2nd-Line Recurrent Brain Tumor Benchmarks NEO100 demonstrates survival outcomes that exceed historical second-line recurrent GBM benchmarks— highlighting a potentially differentiated therapy in a setting with limited effective options and historically low survival rates. Therapy (Setting)
Slide 16: NEO100 Phase II — Registrational Path in IDH1-Mutant Glioma
NEO100 Phase II — Registrational Path in IDH1-Mutant Glioma Objective: Generate confirmatory efficacy and durability data to advance NEO100 toward commercialization Design: Phase II, biomarker-enriched (IDH1-mutant), building directly on Phase I signal Enrollment: 25 patients with recurrent IDH1-mut
Slide 17: NEO100 Phase 2a Demonstrates PFS-6 Above Historical IDH1-Mutant Benchmarks
NEO100 Phase 2a Demonstrates PFS-6 Above Historical IDH1-Mutant Benchmarks Historical Metric NEO100-01 IDH1 mut recurrent HGG1,2 6 months 44% (8/18) 21-31% References: Progression Free Survival 1 Fanucci et al., 2023 ≥6-month follow-up prior to data cutoff. 2 Walbert et al. 2010 Before NEO100 Month
Slide 18: Takeaways from Phase I & II of NEO100
Takeaways from Phase I & II of NEO100 • 6 of 25 (24%) patients achieved significant radiographic remission. This response rate exceeds the <8% typically observed with salvage therapies for recurrent gliomas. • 9 of 25 (36%) patients are long-term survivors, surviving ≥18 months following initiation
Slide 19: NEO100-02 — Intranasal Therapy for Meningioma
NEO100-02 — Intranasal Therapy for Meningioma Large Market: Meningioma is the most common primary brain tumor (~35% of all primary CNS tumors) Prevalence: ~170,000+ patients living with meningioma in the U.S.; 30–35% recur after surgery ± radiation Unmet Need: No FDA-approved systemic therapies for
Slide 20: NEO100-03 — Pediatric High-Grade Glioma (pHGG)
NEO100-03 — Pediatric High-Grade Glioma (pHGG) | Rare Pediatric Disease Opportunity Rare & Lethal: Pediatric HGGs (incl. H3-altered/DIPG) represent ~15–20% of pediatric brain tumors with median OS <12 months Prevalence Threshold Met: ~1,500–2,000 new cases/year worldwide, consistent with Rare Pediat
Slide 21: What Sets Us Apart
What Sets Us Apart NEO100 vs. Current Standard of Care for Recurrent High-Grade Gliomas vs. Current Standard of Care for Recurrent High-Grade Gliomas Repeat Oral Bevacizumab Gamma Gliadel Novocure Surgery Lomustine (Avastin) Tiles Wafers No Surgery Required 1 - - - Bone Marrow Unaffected
Slide 22: NEO100 — Key Upcoming Milestones & Next Steps
NEO100 — Key Upcoming Milestones & Next Steps NEO100-01 (IDH1-Mutant Glioma): Phase II clinical data expected 2H 2026 Regulatory Engagement: Planned interactions with the FDA to define next development steps based on Phase II results Registrational Strategy: Preparation for a registrational Phase II
Slide 23: NEO212
NEONC NEO212
Slide 24: GBM & Temozolomide (TMZ): Fundamental Limitations
GBM & Temozolomide (TMZ): Fundamental Limitations •Foundational standard of care since ~2005, used with surgery and radiation; provides modest median OS benefit (~14-16 months), ~70–80% of patients experience tumor progression within 12 months •Widespread global adoption, with peak sales estimated a
Slide 25: NEO212: Brain-Optimized Temozolomide Bioconjugate
NEO212: Brain-Optimized Temozolomide Bioconjugate Designed to Enhance Brain Tumor Targeting Novel bioconjugate combining NEO100 with temozolomide (TMZ). NEO212 Bioconjugated Molecule Builds on TMZ, the established GBM standard of care, with the goal of improving brain delivery and durability of resp
Slide 26: NEO212 Degrades MGMT and Overcomes TMZ Resistance in GBM
NEO212 Degrades MGMT and Overcomes TMZ Resistance in GBM NEO212 Demonstrates Greater Cytotoxicity Than NEO212 degrades MGMT and Kills TMZ-Resistant GBM Temozolomide in Human GBM Cell Lines Without the Need for MGMT Inhibitor O⁶BG NEO212 Achieves Higher Intratumoral TMZ/AIC Exposure in TMZ-Resistant
Slide 27: NEO212 Demonstrates Enhanced Brain Delivery and Antitumor Activity
NEO212 Demonstrates Enhanced Brain Delivery and Antitumor Activity in TMZ-Resistant GBM BBB penetration ↑ | Overall survival ↑ | Tumor size ↓ ≈3× Higher Brain-to-Serum Intracranial Xenograft Model Increasing NEO212 Levels Observed in Tumor Ratio Observed for NEO212 vs Patient-derived USC-02 MGMT + G
Slide 28: NEO212 Mechanism of Action
NEO212 Mechanism of Action Chen TC et al. Cancer Lett. 2015 Mar 28;358(2):144-151. Cho HY et al. Neurooncol Adv. 2020 Nov 20;2(1):vdaa160. Cho HY et al Mol Cancer Ther. 2014 Aug;13(8):2004-17. 28
Slide 29: NEO212: Novel Alkylating Therapy in Clinical Development for Brain Tumors
NEO212: Novel Alkylating Therapy with Preclinical Evidence of MGMT Inactivation and Brain Penetration in Clinical Development for Brain Tumors Broad Scope: Primary brain tumors and brain metastases as monotherapy and in combination with SOC Differentiation vs TMZ: Up to 10× greater preclinical effic
Slide 30: Phase 1: Safety and Efficacy of NEO212
Phase 1: Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis Phase 1: (dose escalation) Primary Objectives: • Assess the safety and tolerability of increasing dose levels of orally administered NEO212 alone in patients with Astrocytoma
Slide 31: Low Peripheral Blood Detection of NEO212 Metabolites
Low Peripheral Blood Detection of NEO212 Metabolites (AIC and PA) in Phase 1 PK Samples, Consistent with Preclinical Observations of Tumor Uptake and Intratumoral Metabolism Cohort 1 Cohort 2 Cohort 3 Cohort 4 Cohort 5 (170 mg/QD) (220 mg/QD) (400 mg/QD) (610 mg/QD) (810 mg/QD) N (evaluable) 3 3 3 3
Slide 32: 39× Lower AIC Levels Observed with NEO212 vs Temozolomide
39× Lower AIC Levels Observed with NEO212 vs Temozolomide, Reflecting Reduced Systemic Metabolite Levels and Potentially Supporting an Improved Hematologic Safety Profile Adjusted for Body Weight, NEO212 Achieves Higher CNS Delivery vs. TMZ Brain-adjusted exposure NEO212 vs TMZ 200 mg/m² (Cycle 2+)
Slide 33: NEO212 PK: No Clinically Meaningful Myelosuppression Detected
NEO212 PK: No Clinically Meaningful Myelosuppression Detected
Slide 34: NEO212 PK: No Clinically Meaningful Hepatic or Renal/Urinary Toxicity Observed
NEO212 PK: No Clinically Meaningful Hepatic or Renal/Urinary Toxicity Observed
Slide 35: MTD Cohort 5 (810 mg QD) – Key Learnings
MTD Cohort 5 (810 mg QD) – Key Learnings Observed SAEs were consistent with complications commonly seen in advanced recurrent GBM and during temozolomide- Phase 1 dose escalation studies. Brain-adjusted exposure NEO212 vs TMZ 200 mg/m² (Cycle 2+) NEO212 total NEO212 total 5-day dose (TMZ-equivalent,
Slide 36: NEO212 measurable anti-tumor activity in Phase 1
NEO212 measurable anti-tumor activity in Phase 1 36
Slide 37: Partial Response in Recurrent IDH1 Wild-Type GBM
Partial Response Observed in Recurrent IDH1 Wild-Type, MGMT- Methylated GBM – Patient Remains Stable 21 Months Post-Recurrence Screen Cycle 21 Primary Diagnosis: 8/25/2023 Prior Tx: XRT+TMZ (10/23-4/24) Progressed on TMZ After 6 Cycles Contrast NEO212 C1D1: 6/10/2024 Currently on Cycle 22 of NEO212
Slide 38: Lung-to-Brain Metastasis: Last 16 Months on NEO212
Lung-to-Brain Metastasis | 55 Months Since Diagnosis | Last 16 Months on NEO212 Brain Met Diagnosis: Squamous NSCLC (7/20/2021) Prior Tx: Taxol/Carboplatin (7/2018); Keytruda, Alimta (5/2020) NEO212 C1D1: 3/25/2024 Currently on Cycle 16 Screen Cycle 7 Contrast FLAIR 38
Slide 39: NEO212 — Next Potential Steps & Accelerated Regulatory Approval
NEO212 — Next Potential Steps & Accelerated Regulatory Approval Phase I Readout: Initial safety, PK, and preliminary efficacy data Accelerated Approval Strategy: Advancement into Two Phase II Clinical Trials •Trial 1: Randomized evaluation of single-agent NEO212 in recurrent GBM versus standard-of-c
Slide 40: NEO212: Phase 1 Data Informing an Accelerated Phase 2 Strategy
NEO212: Phase 1 Clinical Data Informing an Accelerated Phase 2 Development Strategy in TMZ-Resistant Glioblastoma and Brain Metastases 1. Safety Foundation Established • Phase 1 demonstrated favorable systemic tolerability Why It Matters: Temozolomide’s dose ceiling is bone marrow suppression. NEO21
Slide 41: NeOnc has the potential to become a leader in refractory neuro-oncology
NeOnc has the potential to become a leader in the refractory neuro-oncology market. First-Mover Advantage: Pioneering non-invasive intranasal drug delivery for central nervous system (CNS) diseases Robust IP Protection: Backed by a global portfolio of 179 patents Near-Term Milestones: Several upcomi
Slide 42: Upcoming Milestones
Q1 2026: NEO-212 Phase I Readout – Initial safety, PK, and preliminary efficacy data Q1 2026: NEO-100-03 in Pediatric pHGG – commence enrollment Upcoming Milestones 2H 2026: NEO100-01 – Phase II clinical data in IDH1- Mutant Glioma 2027: NEO100-02 in Meningioma – Phase II clinical study results 42
Slide 43: Contact Us
Contact Us Company Contact NeOnc Technologies Holdings, Inc. 23975 Park Sorrento, Suite 205 Calabasas, CA 91302 Tel +1 (818) 470-NTHI Info@neonc.com www.neonc.com Investor Relations Hayden IR 2369 Lexington Avenue, Second Floor New York, New York 10017 Brett Maas Managing Partner brett@haydenir.com
Slide 44: Appendix
NEONC Appendix
Slide 45: Executive Summary
Executive Summary Founded in 2023, NTHI is a Our platform is designed to Robust IP Portfolio NTHI first mover advantage clinical stage life sciences enable the creation of company. breakthrough drug candidates Holds 179 biotech-related patents Innovative intranasal CNS drug delivery, and cutting-edg
Slide 46: Board of Directors
Board of Directors Victoria Medvec, PhD Bader Al Monawer Jim Delshad Compensation Committee Chair Steven L Giannotta, MD Alan Chiang, MD, PhD. MBA, FICS Audit Committee Chair Corporate Governance Chair 20+ years as CEO of Medvec & More than a decade of Chair Emeritus of Served two terms as Mayor Boa
Slide 47: Senior Management Team
Senior Management Team Our management team possesses significant experience in capital markets, with a track record of building shareholder value in clinical biotech companies. Amir F. Heshmatpour Thomas Chen, MD, Ph.D. Josh Neman , PhD Keithly A. Garnett David Choi, CPA CEO, Founder, CMO & CSO Chie
Slide 48: Scientific Advisory Board
Scientific Advisory Board Our Scientific Advisory Board provides objective perspective and guidance in product development, clinical trials, regulatory compliance, and biotech commercialization strategies. David M. Ashley, MBBS (Hons), Henry S. Friedman, MD Axel H. Schönthal, PhD Alan Chiang, MD, Ph
Slide 49: Middle East Expansion Plan
Middle East Expansion Plan • Integrated GCC/MENA Platform – NuroMENA and NuroCure (controlled by NuroMENA) hold the exclusive sub-license for all 178 NTHI patents in the GCC and MENA. NTHI retains 20% non-dilutive equity and negative control rights over Corporate Board and management. • Government B
Slide 50: NeOnc's Game-Changing Acquisition from McMaster University & USC
NeOnc’s Game-Changing Acquisition from McMaster University & USC Acquisition of SilicoVitro Technology • Strengthens NeOnc’s leadership in next-generation CNS cancer research with SilicoVitro’s AI engine and patented 3D bioprinting platform (US Patent No. 11,788,057 B2) • Accelerates clinical progra
Slide 51: Our Strategic Focus: Deliver Intranasal Chemotherapy to Bypass the Blood-Brain Barrier
Our Strategic Focus: Deliver Intranasal Chemotherapy to Bypass the Blood-Brain Barrier and Directly Target Brain Tumors •Direct Brain Access: Intranasal delivery is designed to enable small-molecule therapeutics to bypass the BBB via the olfactory and trigeminal nerves, reaching the brain through th
Slide 52: The Need: Brain Tumor Statistics
The Need 1 Million 29% #1 American Adults are of Brain Tumors are Brain Tumors are the Living with a Primary Malignant (Cancerous) Leading Cause Of Cancer- Brain Tumor Related Death Among Children 13,657 are Children 94,390 18,990 1-in-143 New Primary Brain Tumors Patients Expected to Lose Your Odds
Slide 53: Pediatric Brain Cancer
Pediatric Brain Cancer The Need The Challenge Our Solution Radiation & chemotherapy for ▪ NEO100: our first therapeutic being Brain Tumors are the Leading children with high-grade developed for pediatric patients #1 Cause of Cancer-Related Death Among Children. gliomas are: diagnosed with pHGGS. Com
Slide 54: The Challenge
The Challenge While the FDA has approved many drugs for treating Malignant Glioblastomas (GBM), survival rates remain low with no significant improvem ent in prognosis over past 50 years. Lack of Progress Primarily Due to Natural Resistance Mechanisms that Limit Efficacy of GBM Treatments Therapeuti
Slide 55: NEO100 Offers Broad Potential for Clinical Benefit and Commercial Application
NEO100 Offers Broad Potential for Clinical Benefit and Commercial Application Designed to act as a When delivered intranasally, When delivered intra-arterially, regulator its small molecular size is it may create a temporary opening for neurologic pathways designed to allow it to bypass in the BBB,
Slide 56: NEO100: Impact & Significance
NEO100: Impact & Significance • First-of-its-kind signal for durable response: MRI- confirmed significant response in setting rarely seen • Potential paradigm shift with multi-year survival: CNS-penetrant metabolic therapy • Differentiation: Minimal toxicity vs. standard salvage therapies • Translat
Slide 57: Sites in pre-activation phase
Sites in pre-activation phase Tufts Medicine Penn State Washington University Johns Hopkins Harvard/ Mass General Hospital New York University Tampa General University of South Carolina Washington University Northwestern University Beverly Hills Cancer Center Pacific Neuroscience Institute Sutter He
Slide 58: Focused on delivery aligned with rapidly expanding global market opportunities
We are focused on delivery of therapeutic innovations aligned with rapidly expanding global market opportunities. Global Market Outlook & Drivers CNS Treatment Market Brain Tumor Drug Market Global, USD Billions 1 Global, USD Billions 2 • Global CNS treatment market is projected to grow at a 8.6% CA
Slide 59: Our Expanding IP Portfolio of Global Patents Creates Competitive Advantages
Our Expanding IP Portfolio of Global Patents Creates Competitive Advantages NEO is a First-of-its-kind Platform Composition & Method Claims Issued & Pending Patent Applications Protected By Patents in the U.S., Canada, NEO100 Ultrapure POH – Issued patents expiring China, UK & EU U.S. Patents in 203
NeOnc Technologies Holdings — Investor Presentation (March 2026) on 6ix